ASH 2023 | The FLIPI24 model for identifying poor outcomes in non-immunochemotherapy treated FL
Carla Casulo, MD, University of Rochester Medical Center-Wilmot Cancer Institute, Rochester, NY, comments on a study which aimed to assess whether the FLIPI24 prognostic model is appropriate for predicting poor outcomes in patients with follicular lymphoma (FL) who have not been treated with immunochemotherapy (IC). High FLIPI24 scores were associated with poorer outcomes, demonstrating that the model holds predictive value in this patient population, not only in patients treated with IC, as previously shown. The model will allow for better stratification of patients and will provide physicians with an indication of which patients are at high risk of experiencing an early disease-related event and may, therefore, need to be treated with novel therapies or enrolled in clinical trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: SecuraBio, GenMab, Bristol Myers Squibb, Gilead Sciences, Verastem, Genentech
Consultancy: Abbvie, Bristol Myers Squibb, Genentech
Leadership role: Follicular Lymphoma Foundation, Lymphoma Research Foundation
